Tibet Aim Pharm Inc Net Asset Quality Index
Tibet Aim Pharm Inc net asset quality index. Tibet Aim Pharm Inc (002826) has a Net Asset Quality Index of 76.0% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.10 Billion minus total liabilities of CN¥265.27 Million yields net assets of CN¥838.02 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Tibet Aim Pharm Inc net assets for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Tibet Aim Pharm Inc (2013–2025)
Net asset quality index of Tibet Aim Pharm Inc from 2013 to 2025. This chart shows how Tibet Aim Pharm Inc's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 76.0%, representing net assets of CN¥838.02 Million against total assets of CN¥1.10 Billion CNY. Check Tibet Aim Pharm Inc (002826) strategic investment index to assess the company's strategic physical and investment asset allocation.
Tibet Aim Pharm Inc Net Asset Quality Index by Year (2013–2025)
Tibet Aim Pharm Inc net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Tibet Aim Pharm Inc from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Tibet Aim Pharm Inc market cap and net worth.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 80.2% | CN¥816.02 Million | CN¥1.02 Billion | CN¥201.65 Million | ▼ -0.3 pp |
| 2024 | 80.5% | CN¥745.58 Million | CN¥926.47 Million | CN¥180.89 Million | ▼ -0.4 pp |
| 2023 | 80.8% | CN¥750.06 Million | CN¥927.74 Million | CN¥177.68 Million | ▲ +7.2 pp |
| 2022 | 73.7% | CN¥750.00 Million | CN¥1.02 Billion | CN¥268.21 Million | ▼ -13.7 pp |
| 2021 | 87.3% | CN¥720.11 Million | CN¥824.47 Million | CN¥104.36 Million | ▲ +11.7 pp |
| 2020 | 75.7% | CN¥687.15 Million | CN¥908.09 Million | CN¥220.94 Million | ▼ -2.4 pp |
| 2019 | 78.1% | CN¥652.17 Million | CN¥835.41 Million | CN¥183.24 Million | ▼ -3.5 pp |
| 2018 | 81.6% | CN¥618.40 Million | CN¥757.93 Million | CN¥139.53 Million | ▼ -0.9 pp |
| 2017 | 82.4% | CN¥604.53 Million | CN¥733.29 Million | CN¥128.76 Million | ▼ -3.5 pp |
| 2016 | 85.9% | CN¥555.44 Million | CN¥646.36 Million | CN¥90.93 Million | ▲ +23.5 pp |
| 2015 | 62.4% | CN¥248.25 Million | CN¥397.70 Million | CN¥149.44 Million | ▼ -4.3 pp |
| 2014 | 66.7% | CN¥179.12 Million | CN¥268.42 Million | CN¥89.30 Million | ▲ +19.9 pp |
| 2013 | 46.8% | CN¥71.66 Million | CN¥153.10 Million | CN¥81.43 Million | — |